Rezafungin
Rezzayo (rezafungin) is a small molecule pharmaceutical. Rezafungin was first approved as Rezzayo on 2023-03-22. It is used to treat candidemia and invasive candidiasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Rezzayo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rezafungin acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| REZZAYO | Mundipharma | N-217417 RX | 2023-03-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rezzayo | New Drug Application | 2024-10-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| candidemia | EFO_1001282 | D058387 | — |
| invasive candidiasis | EFO_1001283 | D058365 | B37 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
REZAFUNGIN ACETATE, REZZAYO, CIDARA THERAPS | |||
| 2035-03-22 | GAIN | ||
| 2033-03-22 | GAIN | ||
| 2030-03-22 | ODE-426 | ||
| 2028-03-22 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | 2 | 2 | 2 | — | 1 | 7 |
| Candidiasis | D002177 | — | B37 | — | 2 | 2 | — | 1 | 5 |
| Candidemia | D058387 | EFO_1001282 | — | — | 1 | 2 | — | — | 3 |
| Invasive candidiasis | D058365 | EFO_1001283 | B37 | — | 1 | 2 | — | — | 3 |
| Fungemia | D016469 | — | B49 | — | 1 | 1 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | — | — | 2 |
| Invasive fungal infections | D000072742 | — | — | 1 | — | 1 | — | — | 2 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | — | 1 | 1 | — | — | 2 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
| Pneumocystis | D011010 | — | — | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vaginitis | D014627 | EFO_0005757 | N76 | — | 1 | — | — | 1 | 2 |
| Vulvovaginal candidiasis | D002181 | EFO_0007543 | B37.3 | — | 1 | — | — | 1 | 2 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rezafungin |
| INN | rezafungin acetate |
| Description | Rezafungin, sold under the brand name Rezzayo, is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal.
|
| Classification | Small molecule |
| Drug class | antifungal antibiotics (undefined group) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](OCC[N+](C)(C)C)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 1396640-59-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989945 |
| ChEBI ID | — |
| PubChem CID | 78318119 |
| DrugBank | DB16310 |
| UNII ID | W1U1TMN677 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,481 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use